Since PRP4K protein expression is variable in breast and ovarian cancer, PRP4K may represent a useful predictive biomarker for taxane response, particularly following relapse in ovarian cancer patients treated with taxanes (Corkery et al., 2018). The gene discussed is PRP4K; the disease is ovarian carcinoma.